---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-25-000016"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T21:21:31.808085+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA

## Summary
- Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).
- FDA accepted troriluzole NDA for spinocerebellar ataxia with Priority Review; PDUFA date in 3Q 2025.
- BHV-1300 (IgG degrader) achieved up to 84% reduction of total IgG in Phase 1; Phase 2 in Graves' disease expected mid-2025.
- Next-gen TRAP degraders BHV-1400 (IgAN) and BHV-1600 (PPCM) advanced; Phase 1 completion expected 1H 2025.
- Multiple pipeline milestones expected: BHV-7000 MDD topline 2H 2025, BHV-8000 Parkinson's study initiation 1H 2025.

## SEC filing metadata
- accession: 0001935979-25-000016
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/0001935979-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/bhvn-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-25-000016
- JSON: https://secwatch.observer/filing/0001935979-25-000016.json
- Plain text: https://secwatch.observer/filing/0001935979-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.